The US Food and Drug Administration (FDA) has absolutely authorised a drug that slows the development of Alzheimer's illness for the primary time.

The FDA has granted full regulatory approval to Leqembi - a drug by Japanese producers Eisai and US drugmakers Biogen.

Up to now, different authorised medication focused solely the signs of the progressive illness, however Leqembi focuses on a protein within the mind, beta-amyloid, believed to be one of many fundamental causes of Alzheimer's.

The FDA's choice got here amid considerations concerning the drug's worth, security and accessibility.

Leqembi will value $26,000 (£20,000) a yr, though Medicare - the US medical health insurance programme primarily for the aged and disabled - is to largely foot the invoice.

When researchers measured the drug's effectiveness in a medical trial, Leqembi slowed down the development of the sickness of these with gentle cognitive impairment or early-stage illness by 27% over an 18-month interval.

However, some medical professionals have criticised it for contributing to mind swelling and haemorrhages - there have been additionally three deaths linked to the drug within the trials.

Read extra:Degenerative brain disease CTE found in female athlete for first timeSmartwatches could help identify symptoms of Parkinson's disease

Leqembi was authorised for individuals with gentle cognitive impairment or early-stage Alzheimer's illness.

The drug is run intravenously each two weeks and consultants advocate sufferers get periodic mind scans to observe for any negative effects.

The Chicago-based Alzheimer's Association praised the FDA's choice.

The therapy may "give people in the early stages of Alzheimer's more time to maintain their independence and do the things they love", Joanne Pike, president and CEO of the Alzheimer's Association, mentioned in a press release.

Ms Pike added: "This gives people more months of recognizing their spouse, children and grandchildren."

Some 6.7 million 65-year-olds and over endure from Alzheimer's within the US, whereas about 900,000 individuals are affected by the sickness within the UK.